Axsome Therapeutics, Inc. (AXSM)
AXSM Price and Sentiment
AXSM Latest news
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time
Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company's migraine drug - AXS-07. AXSM stock has since then rallied 27% to levels of nearly $38 now.
$100 million now available upon the potential FDA approval of AXS-05
Optimism among investors is growing for the possible approval of the biotech's MDD drug.
This biotech is down, but it isn't out just yet.
This beaten-down biotech regained some lost ground last month.
SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Inquire About Class Action Investigation - AXSM2021-09-29 22:03
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public.
Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Among various companies being negatively impacted by a hypersensitive FDA environment, Axsome Therapeutics shares recently tumbled. Amid the aforesaid debacle, AXS-05 received a "stand by" notice from the FDA for its New Drug Application for major depressive disorder.